Melanoma Research最新文献_第8页

Pseudoprogression in a patient with metastatic melanoma treated with PD-1 and LAG-3 inhibition. 一名接受 PD-1 和 LAG-3 抑制剂治疗的转移性黑色素瘤患者出现假性进展。

IF 2.2 4区医学

Melanoma Research Pub Date : 2024-04-18 DOI: 10.1097/cmr.0000000000000974

Lawrence W Wu, Jacqueline J Tao, Diana McDonnell, Benjamin Izar

引用次数: 0

Impact of gene expression profiling on diagnosis and survival after metastasis in patients with uveal melanoma. 基因表达谱分析对葡萄膜黑色素瘤患者转移后的诊断和存活率的影响。

IF 2.2 4区医学

Melanoma Research Pub Date : 2024-04-05 DOI: 10.1097/cmr.0000000000000971

D Suwajanakorn, A M Lane, A K Go, C D Hartley, M Oxenreiter, F Wu, E S Gragoudas, R J Sullivan, K Montazeri, I K Kim

{"title":"Impact of gene expression profiling on diagnosis and survival after metastasis in patients with uveal melanoma.","authors":"D Suwajanakorn, A M Lane, A K Go, C D Hartley, M Oxenreiter, F Wu, E S Gragoudas, R J Sullivan, K Montazeri, I K Kim","doi":"10.1097/cmr.0000000000000971","DOIUrl":"https://doi.org/10.1097/cmr.0000000000000971","url":null,"abstract":"Surveillance frequency for metastasis is guided by gene expression profiling (GEP). This study evaluated the effect of GEP on time to diagnosis of metastasis, subsequent treatment and survival. A retrospective study was conducted of 110 uveal melanoma patients with GEP (DecisionDx-UM, Castle Biosciences, Friendswood, Texas, USA) and 110 American Joint Committee on Cancer-matched controls. Surveillance testing and treatment for metastasis were compared between the two groups and by GEP class. Rates of metastasis, overall survival and melanoma-related mortality were calculated using Kaplan-Meier estimates. Baseline characteristics and follow-up time were balanced in the two groups. Patients' GEP classification was 1A in 41%, 1B in 25.5% and 2 in 33.6%. Metastasis was diagnosed in 26.4% (n = 29) in the GEP group and 23.6% (n = 26) in the no GEP group (P = 0.75). Median time to metastasis was 30.5 and 22.3 months in the GEP and no GEP groups, respectively (P = 0.44). Median months to metastasis were 34.7, 75.8 and 26.1 in class 1A, 1B and 2 patients, respectively (P = 0.28). Disease-specific 5-year survival rates were 89.4% [95% confidence interval (CI): 81.0-94.2%] and 84.1% (95% CI: 74.9-90.1%) in the GEP and no GEP groups respectively (P = 0.49). Median time to death from metastasis was 10.1 months in the GEP group and 8.5 months in the no GEP group (P = 0.40). There were no significant differences in time to metastasis diagnosis and survival outcomes in patients with and without GEP. To realize the full benefit of GEP, more sensitive techniques for detection of metastasis and adjuvant therapies are required.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":"80 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140601358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intracranial hemorrhage caused by dabrafenib and trametinib therapy for metastatic melanoma. 达拉非尼和曲美替尼治疗转移性黑色素瘤引起的颅内出血。

IF 2.2 4区医学

Melanoma Research Pub Date : 2024-04-05 DOI: 10.1097/cmr.0000000000000820

Aymeric Hennemann, Eve Puzenat, Marion Decreuse, Fabrice Vuillier, Charlée Nardin, François Aubin

引用次数: 0

Influence of regression, its extent and tumor-infiltrating lymphocytes on sentinel node status, relapse, and survival in a 10-year retrospective study of melanoma patients. 一项对黑色素瘤患者进行的为期 10 年的回顾性研究显示，退变、退变程度和肿瘤浸润淋巴细胞对前哨节点状态、复发和存活率的影响。

IF 2.2 4区医学

Melanoma Research Pub Date : 2024-04-02 DOI: 10.1097/cmr.0000000000000970

Vincenzo Maione, Martina Perantoni, Luca Bettolini, Stefano Bighetti, Mariachiara Arisi, Cesare Tomasi, Paolo Incardona, Piergiacomo Calzavara-Pinton

{"title":"Influence of regression, its extent and tumor-infiltrating lymphocytes on sentinel node status, relapse, and survival in a 10-year retrospective study of melanoma patients.","authors":"Vincenzo Maione, Martina Perantoni, Luca Bettolini, Stefano Bighetti, Mariachiara Arisi, Cesare Tomasi, Paolo Incardona, Piergiacomo Calzavara-Pinton","doi":"10.1097/cmr.0000000000000970","DOIUrl":"https://doi.org/10.1097/cmr.0000000000000970","url":null,"abstract":"This case-control study seeks to investigate the influence of histological findings, specifically regression, its extent and tumor-infiltrating lymphocyte (TILs), on result of sentinel lymph node (SLN) biopsy, 5-year melanoma-specific survival (MSS), and relapse-free survival (RFS). We included all patients with cutaneous melanoma who underwent SLN biopsy at the Melanoma Center of the University of Brescia, following the Italian Association of Medical Oncology National guidelines from January 2008 to August 2018. Regression and its extent (<75 or ≥75%) and the presence of TILs were reevaluated by a trained dermatopathologist, adhering to the 2017 College of American Pathologists Cancer Protocol for Skin Melanoma. These patients were followed up for 5 years. Our study uncovered significant associations between regression and male sex (P < 0.05), melanoma location on the trunk, upper limbs, and back (P = 0.001), ulceration (P < 0.05), lower Breslow thickness (P = 0.001), and the presence of lymphocytic infiltration (both brisk and nonbrisk) (P < 0.001). Regression and its extent, however, did not appear to affect SLN positivity (P = 0.315). Similarly, our data did not reveal a correlation between TILs and result of SLN biopsy (P = 0.256). When analyzing MSS and RFS in relation to the presence or absence of regression and TILs, no statistically significant differences were observed, thus precluding the need for logistic regression and Kaplan-Meier curve analysis. This study's findings underscore that regression and TILs do not appear to exert an influence on sentinel lymph node status,, MSS, or RFS in our cohort of patients.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":"301 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140602229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Simultaneous melanomas in the setting of multiple primary melanomas. 多发性原发性黑色素瘤中的同期黑色素瘤。

IF 2.2 4区医学

Melanoma Research Pub Date : 2024-04-01 Epub Date: 2024-01-15 DOI: 10.1097/CMR.0000000000000954

Maria Kostaki, Michaela Plaka, Aggeliki Befon, Clio Dessinioti, Katerina Kypraiou, Vasiliki Chardalia, Eleftheria Christofidou, Doris Polydorou, Alexandros Stratigos

{"title":"Simultaneous melanomas in the setting of multiple primary melanomas.","authors":"Maria Kostaki, Michaela Plaka, Aggeliki Befon, Clio Dessinioti, Katerina Kypraiou, Vasiliki Chardalia, Eleftheria Christofidou, Doris Polydorou, Alexandros Stratigos","doi":"10.1097/CMR.0000000000000954","DOIUrl":"10.1097/CMR.0000000000000954","url":null,"abstract":"It is estimated that about 1-13% of melanoma patients will develop multiple primary melanomas. Although the occurrence of subsequent tumors has been described during the last few years, the development of simultaneous melanomas has not yet been extensively studied. We reviewed our registries to identify patients with multiple primary melanomas. We studied epidemiological, clinical, and histological characteristics of patients who were diagnosed with simultaneous melanomas and compared them with those of patients who developed non-synchronous multiple primary melanomas. As simultaneous were defined subsequent melanomas that were diagnosed either at the same visit or within a time-period of maximum of 1 month. Between 2000 and 2020, 2500 patients were diagnosed with melanoma at Andreas Syggros Hospital. 86 (3.4%) patients presented multiple primary melanomas and among them, 35 (40.7%) developed simultaneous melanomas. Patients with simultaneous melanomas developed more frequently more than 2 tumors. First tumors of patients with non-synchronous melanomas were significantly thicker than second tumors while those of patients with simultaneous melanomas did not differ significantly. Slight differences in the tumor localization, staging and histologic type were observed between the two groups. However significant differences were ascertained between first and second tumors in both groups. Simultaneous melanomas occupy an important proportion of multiple primary melanomas, affecting a non-negligible number of patients. Slight differences between simultaneous and non-synchronous multiple primary melanomas seem to define a distinct subcategory of multiple primary melanomas.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"198-201"},"PeriodicalIF":2.2,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139466886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The effect of microRNA-9 overexpression on inhibition of melanoma cancer stem cells tumorigenicity. microRNA-9过表达对抑制黑色素瘤癌干细胞致瘤性的影响

IF 2.2 4区医学

Melanoma Research Pub Date : 2024-04-01 Epub Date: 2024-01-15 DOI: 10.1097/CMR.0000000000000931

Sahranavardfard Parisa, Izadpanah Amirhossein, Yasavoli-Sharahi Hamed, Firouzi Javad, Azimi Masoumeh, Khosravani Pardis, Dorraj Mahshad, Keighobadi Faezeh, Ebrahimi Marzieh

{"title":"The effect of microRNA-9 overexpression on inhibition of melanoma cancer stem cells tumorigenicity.","authors":"Sahranavardfard Parisa, Izadpanah Amirhossein, Yasavoli-Sharahi Hamed, Firouzi Javad, Azimi Masoumeh, Khosravani Pardis, Dorraj Mahshad, Keighobadi Faezeh, Ebrahimi Marzieh","doi":"10.1097/CMR.0000000000000931","DOIUrl":"10.1097/CMR.0000000000000931","url":null,"abstract":"Most of the studies have reported the downregulation of miR-9 in metastatic melanomas compared to primary tumors. They indicated that miR-9 negatively regulates the epithelial-to-mesenchymal transition (EMT) by inhibiting SNAIL1 expression and consequently promotes CDH1 expression. Since the process of EMT is associated to stem cell features, it could be interesting to study the effect of miR-9 on melanoma cancer stem cells. In the present study, we examined the effects of miR-9 manipulation on the stemness potential of melanoma cells. Our data demonstrated that the overexpression of miR-9 in A375 and NA8 cells significantly inhibits the ability of proliferation, self-renewal, migration, and tumorigenicity of melanoma cells which was concomitant with changes in the level of BRAF , some EMT factors, and stemness genes. Likewise, the reduction of miR-9 levels led to an increase in cell proliferation, colony and sphere formation, and the ability of cell migration and tumorigenicity. In conclusion, our results specified the role of miR-9 as a tumor suppressor miRNA to inhibit many aspects of melanoma stem cells, and therefore, it could be a potential candidate for the suppression of melanoma growth and progression.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"105-117"},"PeriodicalIF":2.2,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139466887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hypoxic transcriptomes predict survival and tumor-infiltrating immune cell composition in cutaneous melanoma. 缺氧转录组预测皮肤黑色素瘤的存活率和肿瘤浸润免疫细胞的组成。

IF 2.2 4区医学

Melanoma Research Pub Date : 2024-04-01 Epub Date: 2024-02-07 DOI: 10.1097/CMR.0000000000000938

Michael J Diaz, Jessica Quach, Joanna Song, Silvija Milanovic, Jasmine T Tran, Lauren C Ladehoff, Sai Batchu, Patrick Whitman, Benajmin H Kaffenberger, Marjorie E Montanez-Wiscovich

{"title":"Hypoxic transcriptomes predict survival and tumor-infiltrating immune cell composition in cutaneous melanoma.","authors":"Michael J Diaz, Jessica Quach, Joanna Song, Silvija Milanovic, Jasmine T Tran, Lauren C Ladehoff, Sai Batchu, Patrick Whitman, Benajmin H Kaffenberger, Marjorie E Montanez-Wiscovich","doi":"10.1097/CMR.0000000000000938","DOIUrl":"10.1097/CMR.0000000000000938","url":null,"abstract":"Hypoxia has established associations with aggressive tumor phenotypes in many cancers. However, it is not currently understood whether tumor hypoxia levels map to distinct immune infiltrates in cutaneous melanoma, potentially unveiling novel therapeutic targets. To this end, we leveraged a previously identified seven-gene hypoxia signature to grade hypoxia levels of 460 cutaneous melanomas obtained from the Broad Institute GDAC Firehose portal. CIBERSORTx ( https://cibersortx.stanford.edu/ ) was employed to calculate the relative abundance of 22 mature human hematopoietic populations. Clinical outcomes and immune cell associations were assessed by computational means. Results indicated that patients with high-hypoxia tumors reported significantly worse overall survival and correlated with greater Breslow depth, validating the in-silico methodology. High-hypoxia tumors demonstrated increased infiltration of activated and resting dendritic cells, resting mast cells, neutrophils, and resting NK cells, but lower infiltration of gamma-delta T cells. These data suggest that high tumor hypoxia correlates with lower survival probability and distinct population differences of several tumor-infiltrating leukocytes in cutaneous melanomas.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"118-124"},"PeriodicalIF":2.2,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139702894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating the efficacy of combination and single-agent immunotherapies in real-world patterns of disease progression and survival of metastatic melanoma patients. 根据转移性黑色素瘤患者疾病进展和生存的实际情况，评估联合和单药免疫疗法的疗效。

IF 2.2 4区医学

Melanoma Research Pub Date : 2024-04-01 Epub Date: 2024-01-04 DOI: 10.1097/CMR.0000000000000945

Brian Ko, Kevin Tao, Lachlan Brennan, Swanand Rakhade, Cynthia X Chan, Jee-Young Moone, Richard Zhu, Ariel Sher, Samuel Wang, Yadriel Bracero, Ben Fullerton, Beth McLellan, Larisa J Geskin, Yvonne M Saenger

{"title":"Evaluating the efficacy of combination and single-agent immunotherapies in real-world patterns of disease progression and survival of metastatic melanoma patients.","authors":"Brian Ko, Kevin Tao, Lachlan Brennan, Swanand Rakhade, Cynthia X Chan, Jee-Young Moone, Richard Zhu, Ariel Sher, Samuel Wang, Yadriel Bracero, Ben Fullerton, Beth McLellan, Larisa J Geskin, Yvonne M Saenger","doi":"10.1097/CMR.0000000000000945","DOIUrl":"10.1097/CMR.0000000000000945","url":null,"abstract":"The objective of this study is to describe survival outcomes in patients with metastatic melanoma in a real-world setting receiving combination and single-agent immunotherapy outside the clinical trial context. We conducted a retrospective single-institution study of patients with metastatic melanoma in a real-world setting. Survival was calculated using log-rank test. Contingency tables were analyzed using Fisher's Exact test. CD8 + T-cell densities were measured using quantitative immunofluorescence and analyzed using Mann-Whitney U test. The median overall survival (OS) for 132 patients was 45.3 months. Brain metastasis did not confer a higher risk of death relative to liver and/or bone disease (39.53 versus 30.00 months, respectively; P = 0.687). Anti-PD-1 monotherapy was the most common first-line treatment, received by 49.2% of patients. There was no significant difference in OS between patients receiving single-agent anti-PD-1 and combination anti-PD-1 plus CTLA-4 (39.4 months versus undefined; P = 0.643). Patients treated with combination therapy were more likely to be alive without progression at the last follow-up than those who received monotherapy (70.4% versus 49.2%; P = 0.0408). Median OS was 21.8 months after initiation of second-line therapy after anti-PD-1 monotherapy. CD8+ T-cell densities were higher in patients who achieved disease control on first-line immunotherapy ( P = 0.013). In a real-world setting, patients with metastatic melanoma have excellent survival rates, and treatment benefit can be achieved even after progression on first-line therapy. Combination immunotherapy may produce more favorable long-term outcomes in a real-world setting. High pretreatment CD8+ T-cell infiltration correlates with immunotherapy efficacy.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"134-141"},"PeriodicalIF":2.2,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10906191/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139106391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pregnancy-associated melanoma: characteristics and outcomes from 2002 to 2020. 妊娠相关黑色素瘤：2002 年至 2020 年的特征和结果。

IF 2.2 4区医学

Melanoma Research Pub Date : 2024-04-01 Epub Date: 2024-01-23 DOI: 10.1097/CMR.0000000000000953

Tara M Davidson, Tina J Hieken, Amy E Glasgow, Elizabeth B Habermann, Yiyi Yan

{"title":"Pregnancy-associated melanoma: characteristics and outcomes from 2002 to 2020.","authors":"Tara M Davidson, Tina J Hieken, Amy E Glasgow, Elizabeth B Habermann, Yiyi Yan","doi":"10.1097/CMR.0000000000000953","DOIUrl":"10.1097/CMR.0000000000000953","url":null,"abstract":"Melanoma diagnosed within 1 year of pregnancy is defined as pregnancy-associated melanoma (PAM). No robust data on how pregnancy influences melanoma nor guidelines for PAM management exist. With IRB approval, female patients with a pathology-confirmed melanoma diagnosis within 1 year of pregnancy treated at our institution from 2000 to 2020 were identified. Controls from the cancer registry were matched 1 : 4 when available on decade of age, year of surgery (±5), and stage. We identified 83 PAM patients with median follow-up of 86 months. Mean age at diagnosis was 31 years. 80% AJCC V8 stage I, 2.4% stage II, 13% stage III, 4.8% stage IV. Mean Breslow thickness was 0.79 mm and 3.6% exhibited ulceration. The mean mitotic rate was 0.76/mm 2 . In terms of PAM management, 98.6% of ESD patients and 86.7% of LSD patients received standard-of-care therapy per NCCN guidelines for their disease stage. No clinically significant delays in treatment were noted. Time to treatment from diagnosis to systemic therapy for LSD patients was an average of 46 days (95% CI: 34-59 days). Comparing the 83 PAM patients to 309 controls matched on age, stage, and year of diagnosis, similar 5-year overall survival (97% vs. 97%, P = 0.95) or recurrence-free survival (96% vs. 96%, P = 0.86) was observed. The outcomes of PAM following SOC treatment at a highly specialized center for melanoma care were comparable to non-PAM when matched by clinical-pathologic features. Specialty center care is encouraged for women with PAM.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"175-181"},"PeriodicalIF":2.2,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10906198/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139542698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neonatal cutaneous melanoma with cutaneous metastasis: a case report and review of literature. 新生儿皮肤黑色素瘤伴皮肤转移：病例报告和文献综述。

IF 2.2 4区医学

Melanoma Research Pub Date : 2024-04-01 Epub Date: 2024-02-07 DOI: 10.1097/CMR.0000000000000956

Alp Ercan, Can Ege Yalçin

引用次数: 0